Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01066715 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy
A Phase 2 study, sponsored by Xoma (US).
- Completed
- Registry status
- Phase 2
- Development phase
- 421
- Enrollment target
NCT01066715 is a Phase 2 study that has completed, run by Xoma (US). The registered enrollment target is 421 participants.
The verdict
NCT01066715, a Phase 2 study, has completed, sponsored by Xoma (US).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 421 participants
- Enrollment target
Study Summary
The study hypothesis is that XOMA 052 improves glycemic control in subjects with Type 2 Diabetes. Study X052078 is designed to establish efficacious dose(s) for future studies based on improvement in HbA1c.
Interventions
- DRUG Placebo
- DRUG XOMA 052
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01066715
The ClinicalTrials.gov registry entry for NCT01066715 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 421 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01066715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01066715 about?
NCT01066715 is a clinical study titled "Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy". The study hypothesis is that XOMA 052 improves glycemic control in subjects with Type 2 Diabetes. Study X052078 is designed to establish efficacious dose(s) for future studies based on improvement in HbA1c.
What is the current status of trial NCT01066715?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 421 participants. The study started on 2010-01. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01066715?
The interventions under investigation include: Placebo (DRUG), XOMA 052 (DRUG).
Who is sponsoring clinical trial NCT01066715?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.